Ozempic Constipation: Causes, FDA-Label Rates & Evidence-Based Relief Protocol

Constipation is the second-most-common GI side effect on Ozempic after nausea. The Ozempic FDA label Section 6.1 reports constipation in 3.1% of patients on the 1 mg dose and 5% at higher weight-loss doses studied in SUSTAIN-1^[1][2]. The mechanism is the same one that suppresses appetite: GLP-1 receptor activation slows gastric emptying and reduces overall GI motility^[5]. This guide covers what the trials and the FDA label actually report, when constipation peaks and resolves, the evidence-based relief protocol, and the red-flag warning signs that mean stop self-managing and call your prescriber immediately.

Why Ozempic causes constipation (delayed gastric emptying)

Semaglutide is a GLP-1 receptor agonist. Activation of GLP-1 receptors on enteric neurons slows gastric emptying and reduces overall gut motility — the same mechanism that produces the satiety effect responsible for weight loss^[5]. Marathe and colleagues’ 2013 review in Peptides summarized the physiology: native GLP-1 and pharmacologic GLP-1 receptor agonists delay gastric emptying in a dose-dependent fashion, and this deceleration extends to the small intestine and colon^[5].

In practical terms: food sits in the stomach longer, the small bowel moves contents along more slowly, and the colon has more time to reabsorb water from stool. Drier stool plus slower transit equals the textbook recipe for constipation. The same mechanism that helps you eat less also helps you go less often.

Three additional factors stack on top of the direct motility effect:

• Lower food volume — eating less means less fiber and less stool bulk. A 1,200-calorie day with no deliberate fiber focus often delivers under 10g of fiber, well below the 25-35g/day adult target^[6].
• Lower fluid intake — satiety on a GLP-1 extends to thirst for many patients. Sipping water all day takes conscious effort once the prompt-to-drink-with-meals is gone.
• Concurrent antiemetics — if you’re using ondansetron (Zofran) for nausea, that drug itself causes constipation, and the two effects stack badly. See our nausea management guide for the antiemetic trade-off discussion.

How common: FDA-label + SUSTAIN-1 + STEP-1 incidence

The Ozempic FDA label Section 6.1 reports the following constipation rates from the pooled placebo-controlled trials at the diabetes maintenance doses^[1]:

• Semaglutide 0.5 mg — 3.1% constipation vs. placebo background.
• Semaglutide 1 mg — 3.1% constipation.
• Placebo arm — 1.5% constipation as a background rate.

Higher doses studied for weight loss produce higher rates. SUSTAIN-1, the phase 3a registration trial of semaglutide monotherapy in type 2 diabetes, reported constipation in approximately 5% of patients on semaglutide 0.5 mg and 5% on 1 mg over 30 weeks of treatment^[2]. The STEP-1 obesity trial of semaglutide 2.4 mg (the Wegovy weight-loss dose) reported constipation in roughly 24% of patients vs. 11% on placebo — substantially higher than the Ozempic 1 mg rate, consistent with the dose-response relationship^[3].

Two implications. First, if you’re on Ozempic 0.5 or 1 mg for diabetes, your absolute risk of clinically significant constipation is modest — roughly 1 in 30 patients. Second, if you’re on Wegovy 2.4 mg for weight loss (same molecule, higher dose), constipation becomes much more common and you should plan proactively rather than reactively.

When constipation peaks and resolves

Unlike nausea, which is concentrated in the first 1-2 weeks after each dose step, constipation has a different temporal pattern. In the STEP trials and the SUSTAIN program, GI adverse events were reported as cumulative incidences over the 30-68 week treatment periods^[2][3][4]. The pattern most prescribers see in practice:

• Weeks 1-4 — constipation builds gradually as gut transit slows and food/fluid intake drops. Many patients don’t notice until they realize they haven’t had a bowel movement in 3-4 days.
• Weeks 4-12 — constipation often peaks during this window, especially around dose escalations. Hard, dry stools and infrequent bowel movements (every 3-5 days) are the typical report.
• Months 3-6 — the gut adapts to the slowed motility for most patients. Many report bowel habits stabilizing at a new normal — less frequent than baseline but more predictable.
• Long-term maintenance — STEP-4 reported that GI adverse events including constipation continued at low rates through 68 weeks of continued semaglutide vs. a clear drop after switching to placebo, suggesting the motility effect persists as long as you’re on the drug^[4].

The takeaway: don’t wait until you’re miserable. Start the fiber, fluid, and walking habits from day one of titration, not after week four when you’re already struggling.

First-line relief: fiber, fluids, walking

The first-line relief protocol is conservative and well-supported. It costs nothing, has no drug interactions, and is what most gastroenterologists recommend before any laxative.

Soluble fiber 25-35g/day

Anderson and colleagues’ comprehensive 2009 Nutrition Reviews synthesis documented that dietary fiber consumption above the 25-35g/day adult target improves stool frequency, softness, and transit time, with soluble fiber (psyllium, oat beta-glucan, fruit pectin) showing the most consistent effect on constipation^[6]. On a 1,200-1,500 calorie GLP-1 day, hitting 25-35g of fiber requires deliberate planning — you cannot get there by accident on a typical Western reduced-calorie diet.

• Psyllium husk (Metamucil) — 1 tablespoon (~5g soluble fiber) in a full 8 oz glass of water, 1-3 times daily. The water is non-negotiable; psyllium without enough fluid can worsen constipation.
• Ground flaxseed — 1-2 tablespoons in yogurt, oatmeal, or a smoothie. ~3g fiber per tablespoon plus omega-3s.
• Chia seeds — 1-2 tablespoons, ideally hydrated for 10 minutes in liquid before eating. ~5g fiber per tablespoon.
• High-fiber whole foods — raspberries (8g per cup), pears with skin (5-6g each), avocado (10g each), lentils (15g per cup cooked), black beans (15g per cup), bran cereal (10g+ per serving).

Use our GLP-1 fiber calculator to plan a day that actually hits 25-35g; without planning, most GLP-1 patients land between 8-12g.

Hydration 2.5-3L/day

Fiber without enough fluid is a worse outcome than no fiber. Insoluble fiber needs water to soften stool; soluble fiber needs water to form the gel that lubricates transit. The standard recommendation for an adult on a GLP-1 is 2.5-3 liters of non-caffeinated fluid per day — this is also the volume that protects against the FDA-label acute kidney injury risk (see What NOT to do below)^[1].

Practical patterns that work:

• A 24 oz water bottle next to you all day, refilled three times (totals ~2.1L).
• A full 8 oz glass with each medication or supplement.
• Herbal tea or sparkling water counts toward fluid totals. Coffee counts but is mildly dehydrating at high doses; the net is still positive for most people.

Walking and gentle movement

Physical activity stimulates colonic motility. A 20-30 minute walk after a meal is one of the highest-leverage, zero-side-effect interventions for sluggish bowel transit. The morning is particularly effective because the gastrocolic reflex (colon waking up after the first meal of the day) is the strongest intrinsic peristaltic signal you have.

Pelvic-floor mechanics matter too. Squatting (or using a footstool like a Squatty Potty under the feet during a bowel movement) changes the anorectal angle and reduces the straining required — particularly helpful when stool is harder than usual on a GLP-1.

Second-line: magnesium citrate, osmotic laxatives, stool softeners

If the first-line measures aren’t enough after 7-10 days of consistent effort, second-line options are appropriate. Discuss with your prescriber before starting anything if you have kidney disease, heart failure, or are on multiple other medications.

Magnesium citrate 200-400 mg

Magnesium acts as an osmotic laxative in the colon — it pulls water into the bowel lumen, softening stool and accelerating transit. Mori and colleagues’ 2019 randomized double-blind placebo-controlled trial in the Journal of Neurogastroenterology and Motility demonstrated that oral magnesium oxide improved both stool frequency and consistency in chronic constipation patients vs. placebo over 28 days^[7]. Magnesium citrate is the better-absorbed form for daily use; magnesium oxide is the form studied in the Mori RCT.

• Starting dose — 200 mg magnesium citrate at bedtime. Titrate up to 400 mg if needed and tolerated.
• Side effects — loose stools or diarrhea if you overshoot. Drop the dose if this happens.
• Contraindications — kidney disease (CKD stage 3+), since impaired kidneys can’t excrete excess magnesium. Check with your prescriber if you have any renal impairment.

Polyethylene glycol 3350 (MiraLAX)

PEG 3350 is the over-the-counter osmotic laxative most gastroenterologists recommend for adult constipation. It’s non-absorbed, has minimal side effects, and is safe for long-term use. Dose: 17g (one capful) in 8 oz of fluid once daily; can be increased to twice daily if needed.

Stool softeners (docusate)

Docusate is less effective than osmotic laxatives in randomized trials but can help if your main issue is hard, dry stool rather than infrequency. 100 mg twice daily is the standard dose.

Stimulant laxatives (senna, bisacodyl) — short-term only

Stimulant laxatives work but should be used sparingly — nightly use over weeks-months can lead to dependence in some patients. Reasonable as a 2-3 night rescue when other measures haven’t produced a bowel movement in 4-5 days. Not a long-term strategy.

Red flags: ileus and bowel obstruction

The Ozempic FDA label was updated to include ileus as a postmarketing adverse reaction reported in patients on semaglutide^[1]. Ileus — the functional shutdown of normal bowel peristalsis — can mimic ordinary GLP-1 constipation in its early presentation but progresses to a medical emergency. The distinguishing features:

• No bowel movement for 5+ days AND no passage of gas (this is the cardinal sign — obstipation is more concerning than just constipation).
• Progressive abdominal distension — visibly swollen abdomen that is firm to the touch.
• Severe abdominal pain, especially crampy or colicky pain in waves.
• Vomiting, particularly vomiting of bile (green/ yellow) or feculent (foul-smelling, dark) material.
• Inability to keep down fluids.

Any combination of these symptoms warrants urgent evaluation — call your prescriber immediately, or go to an emergency department if you cannot reach them quickly. Bring your medication or the label so the treating team knows you’re on a GLP-1. Ileus and bowel obstruction can require nasogastric decompression, IV fluids, and in severe cases surgical intervention. The condition is uncommon but the consequences of missing it are serious.

For the full FDA postmarketing label addition and the broader differential between ileus, gastroparesis, and ordinary GLP-1 delayed emptying, see our GLP-1 side effects: what trials actually showed article.

What NOT to do (FDA dehydration + AKI warning)

The Ozempic FDA label Section 5.6 contains an explicit warning about acute kidney injury^[1]: postmarketing reports document AKI — sometimes requiring hemodialysis — in patients on semaglutide, frequently associated with the dehydration that follows persistent nausea, vomiting, diarrhea, or reduced fluid intake. The label specifically instructs prescribers to advise patients on hydration and to monitor renal function when starting or escalating the drug.

Implications for constipation management:

• Don’t megadose osmotic laxatives. A double or triple dose of PEG 3350 or magnesium citrate can induce diarrhea, which combined with reduced GLP-1-driven thirst can drive you into the dehydration-AKI zone the FDA label warns about. Use the recommended doses and titrate gradually.
• Don’t use bowel preps as constipation treatment. A polyethylene glycol bowel prep (4 liters of GoLYTELY or similar) is designed to empty the colon for colonoscopy — it’s not a constipation remedy. The fluid shift is dangerous in a dehydrated patient.
• Don’t skip fluids to “reduce bloating” . Some patients try to fight the bloating component of constipation by drinking less. This is exactly backward and is the fastest path to AKI.
• Don’t add high-dose magnesium if you have kidney disease. CKD stage 3+ patients can develop hypermagnesemia (toxic blood magnesium levels) from oral supplements that healthy kidneys would excrete. Confirm with your prescriber.
• Don’t take stimulant laxatives nightly for weeks. Dependence is a real outcome with chronic stimulant use. Use them as a 2-3 night rescue, not a daily habit.
• Don’t ignore the ileus red flags. The most dangerous mistake is assuming “it’s just my GLP-1 constipation” when the pattern has shifted to obstipation, distension, and vomiting. When in doubt, call.

Pancreatitis (FDA label Section 5.5) is another rare but serious consideration that overlaps with severe GI symptoms^[1]. Severe persistent abdominal pain that radiates to the back, with or without vomiting, warrants prompt evaluation regardless of whether constipation is the dominant symptom.

Related research and tools

• GLP-1 nausea: the practical management guide — the trial rates, timeline, and management tactics for the other major GI side effect
• GLP-1 fatigue: mechanism and management — what to expect when energy drops alongside other GI symptoms
• What to eat the first month on Ozempic — the food framework that builds in fiber and fluid from day one
• GLP-1 side effects: what the trials actually showed — the comprehensive trial-by-trial side-effect table
• GLP-1 side effect questions answered — the Q&A hub with every common patient question
• GLP-1 side effect timeline tool — when each side effect peaks and resolves, by drug and week
• GLP-1 fiber calculator — plan a 25-35g/day fiber target on a reduced-calorie GLP-1 day

Important disclaimer. This article is educational and does not constitute medical advice. Constipation management decisions should always be made with your prescribing clinician, particularly if you have chronic kidney disease, heart failure, or are taking multiple other medications. If you have any of the red flag symptoms listed above (no stool for 5+ days plus abdominal pain or vomiting, progressive distension, inability to pass gas), seek care promptly.